Table 3 Clinical characteristics of study subjects between CAD and control
Variables | CAD patient(n = 256) | Control(n = 49) | Z/t | P value |
|---|---|---|---|---|
Gender(M/F) | 189/67 | 23/26 | -3.740 | < 0.001** |
Age (years) | 66.000(57.000-72.750) | 65.000(54.750–72.250) | -0.720 | 0.471 |
BMI (kg/m2) | 25.028 ± 3.512 | 24.988 ± 3.599 | -0.065 | 0.831 |
Smoking, n (%) | 41.3 | 35.6 | -0.720 | 0.471 |
Drinking, n (%) | 28.9 | 17.8 | -1.535 | 0.125 |
Hypertension, n (%) | 63.0 | 48.9 | -1.781 | 0.075 |
Diabetes mellitus, n (%) | 20.4 | 11.1 | -1.460 | 0.144 |
SBP (mmHg) | 130.317 ± 17.282 | 131.867 ± 18.910 | 0.512 | 0.536 |
DBP (mmHg) | 75.000(69.000–84.000) | 78.000 (72.500–87.000) | -1.780 | 0.075 |
Total cholesterol(mmol/L) | 3.605(3.065–4.373) | 4.075(3.125–4.665) | -1.444 | 0.149 |
TG (mmol/L) | 1.270(0.948–1.713) | 1.205(0.880–1.635) | -0.331 | 0.741 |
HDL-C (mmol/L) | 0.980(0.860–1.135) | 1.085(0.886–1.286) | -2.056 | 0.040* |
LDL-C (mmol/L) | 2.110(1.728–2.705) | 2.230(1.766–2.843) | -0.881 | 0.378 |
GLU (mmol/L) | 5.035(4.518–5.853) | 4.980(4.486–5.650) | -0.777 | 0.437 |
Lp (a) (mg/L) | 172.000(84.000-382.000) | 131.500(61.750–320.000) | -1.110 | 0.267 |
CKMB (ug/dl) | 2.320(1.780–3.150) | 2.330(1.5075–2.998) | -0.711 | 0.477 |
cTnT(ng/dl) | 11.265(6.983–24.323) | 9.400(5.510–20.470) | -2.154 | 0.031 * |
EF value (%) | 62.700(60.700–64.700) | 63.000(61.400-64.725) | -0.884 | 0.377 |
Gensini score | 48.000(24.000-93.750) | 0.000(0.000-4.500) | -10.824 | < 0.001** |
hsa_circRPRD1A | 0.466(0.215–0.728) | 0.613(0.490–1.465) | -2.843 | 0.004* |
hsa_circHERPUD2 | 0.722(0.402–1.633) | 0.976(0.765–1.448) | -2.165 | 0.003 * |
hsa_circLMBR1 | 1.520(0.582–4.384) | 1.286(0.569–4.746) | -0.118 | 0.906 |
hsa_circDHTKD1 | 1.318(0.711–3.988) | 1.062(0.570–1.513) | -1.062 | 0.288 |